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INTRODUCTION
Acute myeloid leukemia (AML) is a highly 
heterogeneous malignant disease of the hematopoietic 
system characterized by a clonal accumulation of immature 
myeloid precursor cells in the bone marrow (BM) and 
peripheral blood (PB) [1]. Structural genetic alterations, 
including gene deletion, inversions and translocations have 
been found in about 55 to 60% of AML patients [1, 2]. 
These alterations, for the most part, represent the initial and 
contributing events leading to malignant transformation 
[1, 2]. Patients with cytogenetically normal AML (CN-
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ABSTRACT
We previously reported that microRNA (miR)-29b is down-regulated and has 
a tumor suppressor role in acute myeloid leukemia (AML). However, little is known 
about the mechanisms responsible for miR-29b expression downregulation in AML. 
In this work we screened for mutations that could affect miR-29b expression. Using 
Sanger sequencing, we identified a germline thymidine (T) base deletion within 
the miR-29b-1/miR-29a cluster precursor in 16% of AML patients. Remarkably we 
found a significant enrichment for the presence of the miR-29 polymorphism in core 
binding factor (CBF) newly diagnosed AML patients (n = 61/303; 20%) with respect 
to age, sex and race matched controls (n = 43/402:11%, P < 0.01). Mechanistically, 
this polymorphism affects the expression ratio of mature miR-29b and miR-29a by 
dampening the processing of miR-29a. RNA immunoprecipitation assays showed 
reduced DROSHA binding capacity to the polymorphism with respect to the controls. 
Finally, we showed that this polymorphism negatively impacts the ability of miR-
29b-1/miR-29a  cluster to target MCL-1 and CDK6, both known miR-29 targets.
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AML) comprise from 30 to 50% of newly diagnosed AML 
cases and exhibit striking differences at the molecular level 
resulting in a substantial heterogeneity in terms of clinical 
outcome [1–5].
Over the past decade, a novel class of small non-
coding RNAs, named microRNAs (miRNAs) have 
been shown to regulate gene expression by binding to 
target mRNAs of protein-coding genes and inhibiting 
protein translation and/or causing RNA degradation [6]. 
Deregulation of miRNAs, and in turn their target genes, 
has been found to contribute to malignant transformation in 
several human solid tumors and hematologic malignancies 
by interfering with the expression of proteins involved in 
critical cell processes such as development, differentiation, 
proliferation and apoptosis [6, 7]. We and others have shown 
unique miRNA expression signatures that are associated 
with genetic and molecular subsets of AML [8–12]. 
Among the miRNAs whose expression is deregulated in 
AML, we have focused on miR-29 family members for 
several reasons. First, the miR-29 family is composed of 
3 isoforms arranged in 2 clusters: miR-29b-1/miR-29a 
located on chromosome 7q32 and miR-29b-2/miR-29c 
located on chromosome 1q23. Interestingly, chromosome 
7q32 is a region frequently deleted in myelodysplastic 
syndromes (MDSs) and therapy-related AML [13]. 
Second, miR-29 family members have been shown to be 
down-regulated in several cancers including high-risk 
chronic lymphocytic leukemia (CLL) [14], lung cancer 
[15], invasive breast cancer [16], cholangiocarcinoma [17] 
and rhabdomyosarcoma [18]. Third, we have previously 
shown that miR-29b expression is down-regulated in CN-
AML with wild type nucleophosmin (NPM1) [19], c-KIT 
mutated core binding factor (CBF) [20], monosomy 7 
or del7q [21] and t(11q23) [8] patients. Last, restoration 
of miR-29b expression in AML cell lines and primary 
AML blasts induces apoptosis and dramatically reduces 
tumorigenicity in a xenograft leukemia model [21].  We have 
also shown that miR-29b is central to regulation of both 
DNA methylation and tyrosine kinase receptor activities in 
leukemia cells [20, 22]. Altogether, these studies support a 
tumor suppressor function for miR-29b in AML. 
However, with the exception of AML cases where 
chromosome 7 is deleted [21], little is known about how 
miR-29b expression is down-regulated in AML. Since 
miRNAs expression could be lost due to mutations [14], in 
this work we screened AML patient samples for mutations 
that could affect miR-29b expression and function.
RESULTS
A thymidine (T) base deletion polymorphism 
within the miR-29b-1/miR-29a cluster precursor 
is enriched in core binding factor AML 
To screen for mutations that may affect miR-29b 
expression, we sequenced the whole miR-29b-1/miR-29a 
cluster genomic DNA region located in chromosome 7q32 
(including 200 base pairs (bp) at the 5′ of the miR-29b-1 
and at the 3′ of the miR-29a precursor, Figure 1A) in a 
representative cohort of 100 primary AML samples (MD 
Anderson cohort, See Table 1 for patient characteristics). 
We focus on this cluster because it is located in a fragile 
genomic area that is commonly deleted and mutated in 
hematological malignancies, including AML [13]. Using 
Sanger sequencing we identified a (T) base deletion within 
the miR-29b-1/miR-29a cluster precursor miRNAs (at 
–385 bp from the 3′ position of the miR-29b precursor and 
–264 bp from the 5′ position of miR-29a in chromosome 
7q32) in 16/100 (16%) patients (Chr7:130,877,074delT) 
(Figure 1B). This deletion correspond to an A base 
deletion described in the positive (+) strand at the same 
position (rs67760566) in the dbSNP database; http://
www.ncbi.nlm.nih.gov/SNP/. The T base deletion was 
observed in 3/10 inv(16) and 7/62 CN-AML patients, 
while the other 6 cases were distributed among complex 
karyotype (CK) (2/11), isolated –7 (1/5), 11q23 (1/4) and 
other cytogenetics (2/5). For the most part, the T base 
deletion was heterozygous (n = 14), while in the cases of 
isolated monosomy 7 and in –7 associated with CK, the 
remaining alleles have the T base deletion. To investigate 
whether this genomic finding was somatic or germline, 
we sequenced the same genomic region but using buccal 
mucosa DNA from two patients who were identified 
as positive for the T base deletion. We confirmed that 
the same heterozygous T base deletion was observed 
in these two cases, supporting a germline origin (data 
not shown). Next, to investigate the frequency of this 
abnormality in the healthy population, we sequenced 
only the genomic area where this T base deletion was 
observed (about 200 bp) using genomic DNA obtained 
from PB mononuclear cells of 402 healthy individuals of 
similar sex and race to the MD Anderson leukemic cohort, 
except for White-Hispanics that were more frequent in the 
MD Anderson cohort (n = 14/100) vs. the OSU healthy 
controls (n = 29/402), P = 0.04 (Supplementary Table 1). 
We found that the frequency of this polymorphism in the 
control healthy population was 11% (43/402 cases) (38 
heterozygous and 5 homozygous) (Supplementary Table 1 
and Table 2). There were no differences with respect to the 
frequency of this polymorphism according to race or sex 
(Supplementary Table 2). The frequency of the miR-29 
polymorphism was not significantly different between 
AML cases (n = 100: 16%) and controls (n = 402: 11%, 
P = 0.16). While not statistically significant, we found an 
enrichment for the presence of the miR-29 polymorphism 
in AML cases with CBF leukemia (n = 3/12: 25%) 
compared to controls (n = 43/402:11%) (Supplementary 
Table 1 and Figure 1C). To further explore this finding 
we screened for the presence of this polymorphism in a 
larger second cohort of 303 samples of newly diagnosed 
AML patients with t(8;21) (n = 131) and inv(16) 
(n = 172) obtained from the CALGB/ Alliance leukemia 
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tissue bank (See Tables 2 and 3 for patients characteristics). 
The polymorphism frequency was significantly higher 
in CBF leukemia (61/303, 20%) than healthy controls 
(43/402, 11%) of similar sex and race (P < 0.01) (Table 2 
and Figure 1C). Only 8 of the 61 CBF-AML patients 
with polymorphism were homozygous for the finding. 
There were no significant differences in baseline clinical 
characteristics among inv(16) and t(8;21) patients with 
or without the polymorphism (Table 3), except in t(8;21) 
AML cases for age (median polymorphism 45 vs. median 
no polymorphism 37, P = 0.04), race (white  polymorphism 
n = 17 (61%) vs. white no polymorphism n = 91 (90%) 
(P < 0.01); platelet count (median polymorphism 
47 × 109/L vs. median no polymorphism 36 × 109/L, 
P = 0.03) and percentage of blasts in peripheral blood 
(median polymorphism 28 vs. median no polymorphism 
39, P = 0.04).
Prognostic impact of the miR-29 polymorphism 
in CBF leukemia
To investigate whether this polymorphism has 
any prognostic impact in CBF-AML, we assessed the 
frequency of complete response (CR), event free-survival 
(EFS) and overall survival (OS) according to the miR-29 
polymorphism status in a subset of de novo inv(16) 
(n = 126) and t(8;21) (n = 100) AML patients treated with 
intensive cytarabine/-anthracycline-based first-line therapy 
on CALGB/ Alliance trials and whose clinical follow-up 
information was available. 
First, we investigated whether the presence of the 
polymorphism predicts induction chemotherapy response. 
We did not observed any differences in the CR rates among 
the patients with and without the polymorphism; CR 
response rate for t(8;21) cases with miR-29 polymorphism 
Figure 1: Frequency of thymidine (T) base deletion (rs67760466) in acute myeloid leukemia (AML). (A) Diagram showing 
both miR-29 clusters and the location of the T base deletion. (B) Chromatograms showing a wild type (WT) and a polymorphism case. 
(C) Frequency of the polymorphism (rs67760466) in AML patients and in controls. P values were obtained using the Fisher’s exact test. 
Patient characteristics are detailed in Tables 1 and 2.  
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n = 19 (90%) vs. cases with no miR-29 polymorphism 
n = 76 (96%) (P = 0.28); inv(16) cases with miR-29 
polymorphism n = 25(100%) vs. no miR-29 polymorphism 
n = 98 (97%) (P = 1.00). Likewise, there were no statistical 
significant differences in EFS or OS between CBF patients 
with or without miR-29 polymorphism (Supplementary 
Figure 1A–1D). These results also held when considering 
patients with high risk CBF leukemia based on the presence 
of c-KIT mutation (Supplementary Figures 2A–2D 
and 3A–3D). 
The miR-29b-1/miR-29a cluster processing is 
affected by the T base deletion polymorphism
To investigate whether this polymorphism affects 
miR-29b or miR-29a mature expression we measured 
miR-29b and miR-29a expression in 45 from the 100 
primary AML samples (MD Anderson data set), where 
RNA was also available. Although mature miR-29a 
and miR-29b levels were not significantly different in 
polymorphism (n = 10) versus WT (n = 35) samples 
(data not shown), we observed that the miR-29a/miR-29b 
ratios were significantly lower in the polymorphism than 
WT samples (23.2 vs. 43.5 respectively, P = 0.02, t-test) 
(Figure 2A). These results suggest that the processing of 
this miRNA cluster is altered by the polymorphism. To 
confirm this possibility, we cloned the miR-29b-1/miR-
29a cluster from 1 patient harboring the polymorphism 
into p-Retro Super plasmid and transfected into K562 
cells (which have very low levels of endogenous 
miR-29 expression) along with WT (miR-29b-1/miR-
29a cluster with no polymorphism) and empty vector 
constructs. Northern blotting performed 24 and 48 
hours after transfection revealed an accumulation of the 
miR-29a precursor while the mature miR-29a level was 
decreased by 2 fold at 48 and 72 hours (Figure 2B and 
Supplementary Figure 4). While the precursor of miR-29b 
was also increased at 24 and 48 hours after transfection, 
the level of mature miR-29b was unchanged for all time 
points (up to 72 hours). Taken together, these data support 
that the polymorphism affects the processing of miR-29a. 
Given that Drosha complex is required for the processing 
of the primary transcript primiR-29b-1/miR-29a, we 
evaluated the efficiency of the interaction between the 
DROSHA complex and the primiR-29b-1/miR-29a by 
performing RIP assays in K562 ells transfected with either 
Table 1: Patient characteristics for MD Anderson cohort
Characteristic Value 
Age
        Median 56
        Range 17–82
Sex,  no.
        Female                              47
        male                                  53
Race,  no
        White 92
        Non-white 8
            Asian 1
            Black 7
Cytogenetics, no. 
   t(15;17) 1
   inv(16) 10
   t(8;21) 2
   t(11q23) 4
   Complex karyotype (CK) 11
    isolated 7 5
   Other cytogenetics 5
   Normal Karyotype 62
           FLT3-ITD 18
           NPM1 34
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miR-29b-1/miR-29a polymorphism, miR-29b-1/miR-29a 
WT or empty vector construct. As shown in Figure 2C, the 
polymorphism showed reduced Drosha binding capacity 
when compared with the WT.
The polymorphism dampens the targeting 
efficiency and tumor suppressor function of miR-
29b-1/miR-29a cluster
To assess whether this polymorphism affects miR-
29 targeting efficiency, we co-transfected a reporter 
luciferase construct containing the 3′ untranslated 
region (3′UTR) of two known miR-29 target oncogenes, 
MCL-1 and CDK6 [21] with the WT, empty vector and 
polymorphism harboring miR-29b-1/miR-29a cluster 
and performed luciferase assays. Interestingly, relative 
normalized luciferase activities were less inhibited with 
the polymorphism cluster than the WT construct for 
MCL-1 (relative reduction WT: 63%, polymorphism: 
80%, P = 0.02, t-test) (Figure 3A) and for CDK6 (relative 
reduction WT: 37%, polymorphism: 68%, P < 0.01, 
t-test) (Figure 3B). Next, we investigated whether the 
effects observed at the luciferase assays were translated 
to the protein level. Indeed, we showed that Mcl-1 and 
Cdk6 protein down-regulation elicited by the ectopic WT 
cluster overexpression was stronger than the one observed 
for the cluster harboring the polymorphism (Figure 3C 
and 3D). Finally, we investigated whether the less efficient 
reduction in Mcl-1 protein expression caused by the 
polymorphism was functionally important. Since Mcl-1 
is an anti-apoptotic protein [21], we compared apoptosis 
induction between the WT and polymorphism miR-29b-1/
miR-29a cluster over-expression in K562 cell lines. In 
Figure 3E, we showed that the miR-29b-1/miR-29a cluster 
harboring the polymorphism exhibited less apoptosis that 
the WT with respect to controls (empty vectors). 
DISCUSSION
Our results identify a germline polymorphism 
within the miR-29b-1/miR-29-a cluster, whose frequency 
is increased in the subset of CBF-AML patients with 
respect to the normal population. These results were 
further validated using a second independent large cohort 
of 303 de novo CBF-AML patients (including both 
inv(16) and t(8;21)). The causes for such an increased 
frequency of this polymorphism in this AML subset are 
unknown. Interestingly, miR-29b plays a critical role in 
c-KIT oncogene expression regulation in CBF leukemia by 
dampening c-KIT oncogene transcription through the direct 
targeting of its activator Sp1 [20]. Ectopic overexpression 
of miR-29b in CBF-cell lines and in a murine AML model 
Table 2: Patient characteristics and results for CALGB/ Alliance cohort and controls
*P values *P values *P values
t(8;21) inv(16) All Cases  Controls t(8;21) vs. inv(16) vs. All cases vs.
Characteristic (n = 131)  (n = 172)  (n = 303)  (n = 402) controls controls controls
Age
  Median 38 38 38 42 0.07 <0.01 <0.01
  Range  (17–71)  (17–60)  (17–71)  (18–61)
Sex, no. (%)
  Male 78 (60) 107 (62) 185 (61) 232 (58) 0.76 0.35 0.40
  Female 53 (40) 65 (38) 118 (39) 170 (42)
Race, no. (%)
   White 108 (84) 149 (89) 257 (87) 360 (91) 0.03# 0.53# 0.11#
   Non-white 21 (16) 18 (11) 39 (13) 36 (9)
      Asian 4 0 4 11
      Black 13 16 29 25
      Other 2 2 4 0
      Unknown 2 5 7 6
Polymorphism, no (%)
     Yes 28 (21) 33 (19) 61 (20) 43 (11) <0.01 <0.01 <0.01
     No 103 (79) 139 (81) 242 (80) 359 (89)    
*P-values for categorical variables were obtained using Fisher exact test, P-values for continuous variables are from 
Wilcoxon rank sum test.
#P-value is for White versus Non-white comparison.
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Table 3: Clinical and molecular characteristics by polymorphism status in CALGB/ Alliance t(8;21) and inv(16) AML 
patients
t(8;21) inv(16)
Polymorphism
No 
Polymorphism Polymorphism
No 
Polymorphism
Characteristic (n = 28)  (n = 103) *P values  (n = 33)  (n = 139) *P values
Age
  Median 45 37 0.04 36 40     0.31
  Range  (19–69)  (17–71)  (17–57)  (18–60)
Sex, no. (%)
  Male 17 (61) 61 (59) 1.00 20 (61) 87 (63) 0.84
  Female 11 (39) 42 (41) 13 (39) 52 (37)
Race, no. (%)
   White 17 (61) 91 (90) <0.01# 26 (81) 123 (91) 0.12#
   Non-white 11 (39) 10 (10) 6 (19) 12 (9)
      Asian 3 1 0 0
      Black 6 7 6 10
      Other 0 2 0 2
unknown 0 2 1 4
Hemoglobin (g/dl)
     Median 8.7 8.8 0.92 9.4 8.7 0.07
     Range  (5.9–13.3)  (3.5–12.7)  (6.3–12.3)  (3.1–14.8)
Platelet count (x109/L)
    Median 47 36 0.03 45 40 0.43
    Range  (7–227)  (5–369)  (9–113)  (7–272)
WBC count (x109)
     Median 11.8 10.8 0.53 36.0 32.53 0.98
     Range  (2.2–59.2)  (0.7–138.9)  (0.4–265)  (1.8–500)
% Blood blasts
     Median 28 39 0.04 53 54 0.88
     Range  (6–90)  (0–92)  (12–84)  (0–97)
% Bone Marrow blasts
     Median 56 49 0.68 57 58 0.59
     Range  (21–83)  (11–97)  (22–86)  (2–93)
C-KIT, no. (%)
Mutated 8 (30) 24 (24) 0.62#$ 9 (27) 34 (24) 0.82$
  exon 17 5 17 2 11
  exon 8 2 6 6 21
  Both 1 1 1 2
Wild-type 19 (70) 76 (76) 24 (73) 105 (76)
unknown 1 3     
*P-values for categorical variables were obtained using Fisher exact test, P-values for continuous variables are from 
Wilcoxon rank sum test.
#P-value is for White versus Non-white comparison. 
$P-value is for mutated versus wild-type comparison.
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represses c-KIT expression and induced cell death [20]. 
The fact that the miR-29 polymorphism is more prevalent 
in CBF leukemia, further support the important functional 
role of miR-29 in CBF-leukemia.
Another interesting finding from our work was 
the finding of this polymorphism in patients with 
isolated chromosome 7 monosomy (1/6). We have 
previously shown that patients with monosomy 7 and 
del7q primary AML blasts, have lower miR-29a and 
miR-29b expression levels than AML blasts without any 
chromosome 7 abnormalities, indicating that the structural 
genomic deletion is responsible for the decreased miRNA 
expression since this cluster is located in chromosome 
7q32 [21]. The finding of a polymorphism that affects 
the expression and function of this cluster in the other 
allele of AML patients with monosomy 7 is intriguing and 
may contribute to further inactive the tumor suppressor 
functions of the miR-29 cluster. 
Mechanistically, this polymorphism affects the 
expression ratio of mature miR-29b and miR-29a 
by dampening the processing of miR-29a. Northern 
blotting showed accumulation of miR-29 precursors 
with an associated decrease in the expression of mature 
miR-29a. The levels of mature miR-29b however, were 
unchanged with respect to the WT controls. Interestingly, 
the polymorphism is between miR-29b-1 and miR-29a 
and after the miR-29b transcription initiation site, a 
possible explanation as to why the polymorphism does 
not have an effect on mature miR-29b. In the presence 
of reduced mature miR-29a, the accumulation of the 
Figure 2: The miR-29b-1/miR-29a cluster processing is affected by the T base deletion polymorphism in acute myeloid 
leukemia. (A) miR-29b-1/miR-29a expression ratios in wild type (WT) (n = 35) vs. polymorphism (Poly) cases (n = 10) as measured by 
quantitative real time RT-PCR.  (B) Northern Blotting (NB) of miR-29b-1/miR-29a after transfection with empty vector (EV), WT or Poly 
constructs. U6 was used as loading control. (C) RNA immunoprecipitation assays in K562 cells transfected with miR-29b-1/miR-29a Poly, 
WT or EV construct.
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miR-29a precursor suggests that a problem exists in the 
processing of miRNA. Previous groups including our own 
have shown that mutations or polymorphisms affecting the 
precursor miRNA can affect the miRNA processing and 
results in precursor accumulation and decreased mature 
miRNA expression [14, 28]. Notably, in the case of the 
polymorphism described here the deletion is outside the 
miRNA precursor, indicating that the genomic region 
between the two miRNAs is important for miRNA 
processing of one of the mature miRNAs in the cluster. 
The aberrant ratios between miR-29a and miR-29b 
resulting from the polymorphism found in the experimental 
studies were also confirmed in primary AML samples. 
This finding raises the question about the significance 
and contribution of the different expression levels among 
members of this cluster to the functions of miR-29 in normal 
physiological conditions and in disease. We previously 
found significant differences in the expression of genes 
correlated with miR-29a or miR-29b expression in primary 
AML samples, indicating non-overlapping functions for 
miR-29a and miR-29b in AML [21]. It is likely that a tight 
balance between the expression of both mature miR-29a 
and miR-29b exists and alterations in the expression ratios 
between them may affect the functions of both miRNAs. 
Supporting this, we showed that this polymorphism 
negatively impacts the ability of this cluster to target the 
oncogenes MCL-1 and CDK6, both known miR-29 targets.
In summary, we discovered a polymorphism in the 
miR-29b-1/miR-29a cluster that is enriched in CBF-AML 
cases. This polymorphism affects miR-29b-1/miR-29a 
cluster processing, resulting in accumulation of the 
precursor, and low levels of mature miR-29a. Functionally, 
the polymorphism impacts the ability of the cluster to 
target MCL-1 and CDK6 and induce apoptosis. 
Figure 3: The polymorphism dampens the targeting efficiency and tumor suppressor function of the miR-29b-1/
miR-29a cluster. (A) MCL-1 and (B) CDK6 luciferase Assays. MiR-29b-1/miR-29a wild type (WT), polymorphism (Poly) or empty 
vector (EV) constructs were co-transfected with luciferase reporters containing the 3′untranslated regions (UTR) of MCL-1 or CDK6. The 
results are shown as relative luciferase values with respect to the EV after normalization with renilla. (C) Western Blotting for Mcl-1 and 
(D) Cdk6 proteins in K562 cells after transfection with miR-29b-1/miR-29a WT, Poly or EV constructs. GAPDH was used as loading 
control. As a control we also transfected cells with scramble (SC) or miR-29b (29b) oligonucleotides. (E) Apoptosis as measured using 
Annexin V/propidium iodine stain in K562 cells after transfection with miR-29b-1/miR-29a WT, Poly or EV constructs.
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MATERIALS AND METHODS
Patients samples
Frozen diagnostic BM or (PB) samples were obtained 
from adult AML patients from the MD Anderson Tissue 
bank (n = 100) and from the Cancer and leukemia group 
B (CALGB)/ Alliance leukemia tissue bank (n = 303). 
Cytogenetic analyses of the samples were performed at 
diagnosis, using unstimulated short-term (24-, 48-, and 
72-hour) cultures with or without a direct method and 
G-banding. For the CALGB/-Alliance dataset, cytogenetic 
analyses at diagnosis were performed by CALGB–
approved institutional cytogenetic laboratories as part of 
the cytogenetic companion study 8461 and confirmed by 
central karyotype review.  The criteria used to describe a 
cytogenetic clone and description of karyotype followed 
the recommendations of the International System for 
Human Cytogenetic Nomenclature [23]. FLT3-ITD, FLT3 
activation loop D835 and NPM1 mutations analyses were 
performed on most of the samples using Sanger sequencing 
as previously described [8]. All patients gave informed 
consent for cryopreservation and use of the samples 
for molecular studies. Approval was obtained from the 
institutional board review from the MD Anderson Cancer 
Center and The Ohio State University. DNA from the blood 
of 402 control healthy subjects was obtained from the Ohio 
State University Human Genetics Sample Bank.
Mutation screening
 To screen for mutations or polymorphisms, the 
entire genomic region from primary AML samples, 
corresponding to the miR-29b-1/miR-29-a cluster 
precursor, located in chromosome 7q32, including 200 bp 
at the 5′ and 3′ ends was amplified and sequenced using 
the Applied Biosystems DNA sequencing system (Applied 
Biosystems, Foster City, CA). When a deviation from the 
normal sequence was found, a panel of DNA from the 
blood of 402 control subjects was screened to identify 
polymorphisms.
Real-Time quantification of miRs and target 
genes
The single tube TaqMan miRNA assays were used 
to detect and quantify mature miR-29a and miR-29b 
expression as previously described [24] using PCR 9700 
Thermocycler ABI Prism 7900HT and the sequence 
detection system (Applied Biosystems). To detect the 
Myeloid Cell Leukemia sequence 1 (MCL-1) and the 
Cyclin-Dependent Kinase 6 (CDK6) mRNA levels, we 
used the TaqMan gene expression assays. Normalization 
was performed with 18s and U6. Comparative real-time 
PCR was performed in triplicate, including no-template 
controls. Relative expression was calculated using the 
comparative Ct method [25].
Cell transfection with miRNA expression vectors 
and miRNA precursors
The genomic region corresponding to the miR-29b-1/
miR-29a cluster (200 bp before and after precursor) from a 
wild type (WT) or a polymorphism patient was cloned into 
the pSuperRetro expression vector (OligoEngine, Seattle, 
WA). The miRNA precursor miR-29b was purchased from 
Ambion (Austin, TX). Five million K562 cells (ATCC, 
Manassas, VA) were nucleoporated using AMAXA 
(Gaithersburg, MD) with 5ug of vectors pSuperRetro-miR-
29a-1/miR-29b-WT, pSurperRetro-miR-29a-1/miR-29b-
Polymorphism and empty vector or with 5 ug of precursor 
oligonucleotides (miR-29b or scrambled controls) in a total 
volume of 10 ml.  
Northern blotting
Northern Blotting was performed as previously 
described [19]. Briefly, total RNA was extracted using 
Trizol reagent (Invitrogen, Carlsbad, CA). RNA samples 
(10 ug) were run on 12% polycramide denaturing (urea) 
precast gels (BIO-RAD, Hercules, CA) and then transfered 
onto Hybond membrane (Amersham Pharmacia Biotech, 
Uppsala, Sweden). The hybridization was performed with 
α-32P miR-29a and -b labeled probes overnight at 42ºC. 
The miR-29 probes sequences were the complementary 
one to the mature miR-29s.  As a loading control we 
measured U6 expression after stripping the filter as 
previously described [19].
RNA immunoprecipitation assay (RIP)
RIP was performed with the Magna RIP kit 
(Millipore, Billerica, MA) according to the manufacturer’s 
instruction. Cells transfected with vectors pSuperRetro-
miR-29a-1/miR-29b-WT, pSurperRetro-miR-29a-1/miR-
29b-Polymorphism and empty vector, were lysed and the 
RNA associated proteins were immunoprecipitated (IP) 
with Drosha Antibody Cat. Number A301-886A (Bethyl 
Laboratories, Montgomery, TX). RNA was extracted from 
the Drosha immunoprecipitated complex by following 
the protocol provided by the kit and quantified with 
Nanodrop2000 (Thermo-Scientific, Waltham, MA). Total 
RNA (25 ng) was retro-transcribed with High Capacity 
cDNA Reverse Transcription Kit (Lifetech, Carlsbad, 
CA). The primiR-29b-1/miR-29a exogenous expression 
was assessed by quantitative real time PCR (SYBR green, 
Qiagen, Hilden, Germany) and referenced to the non-
immunoprecipitated control (Input) using the following 
primers: primiR-29a1/miR-29b Fwd: 5′- CAT ATA TCA 
CAA ATG GCA GTC AGG TCT -3′ and Rev: 5′- TGT 
ACA GGA TAT CGC ATT GTT GGA A-3′. Real time 
PCRs were performed in an Applied Biosystems 7500 
instrument. MiRNA expression was measured using Ct 
(threshold cycle). 
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Statistical analysis
Fisher’s exact test and t-test were used to compare 
baseline characteristics and average miRNA expression 
between groups of patients [26]. These reported P values 
were two-sided and obtained using the SPSS software 
package (SPSS 10.0). Baseline demographic, clinical, and 
molecular features were compared between the Alliance/
CALGB cohort and controls and between polymorphism 
and no polymorphism using the Wilcoxon rank sum and 
Fisher’s exact tests for continuous and categorical variables, 
respectively [26]. The estimated probabilities of event-free 
(EFS) and overall survival (OS) were calculated using the 
Kaplan–Meier method, and the log-rank test evaluated 
differences between survival distributions [27]. Clinical 
endpoint definitions are given in the Data Supplement. All 
statistical analyses were performed by the Alliance Statistics 
and Data Center on a database locked on June 16, 2016 
using SAS 9.4 and TIBCO Spotfire S+ 8.2.
Luciferase reporter experiments
The 3′ UTR segment containing the target sites 
for miR-29b  from the MCL-1 gene was  amplified by 
PCR from genomic DNA and inserted into the pGL3 
control vector  (Promega, Madison, WI), using the XBA1 
site immediately downstream from the stop codon of 
luciferase. The following primer sets were used to generate 
specific fragments: MCL-1 FW 5′TGGAACTCATT 
AGCTGTGTGC3′, and RW 5′GATGCCAATGCAAAA 
ACTTG 3′. We also generated an insert with deletions of 
4 bp from the site of perfect complementarity using the 
Quiagen XL-site directed Mutagenesis Kit. Wild type and 
mutant insert were confirmed by sequencing. Human cell 
line K562 was grown in 10% fetal bovine serum in RPMI-
1640. The cells were cotransfected in 10 ml plates using 
nucleoporation (Amaxa) according to the manufacturer’s 
protocol using 5 ug of the firefly luciferase report vector 
and 0.5 ug of the control vector containing Renilla 
luciferase, pRL–TK (Promega) along with 5 ug of the 
pSuperRetro-miR-29a-1/miR-29b-WT, pSurperRetro-
miR-29a-1/miR-29b-Polymorphism or empty vector. 
Firefly and Renilla luciferase activities were measured 
consecutively using the dual luciferase assays (Promega) 
24 hrs after transfection.  
Apoptosis experiments
Annexin V/ Propidium iodide stain (BD Pharmingen, 
San Diego, CA) was performed at different time points 
after nucleoporation with pSuperRetro expression vectors 
as described above. 
Western blotting
Total protein extracts from K562 transfected cells 
with pSuperRetro expression vectors were extracted using 
RIPA buffer (SIGMA, St Louis, MO). Protein expression 
was analyzed by Western blotting using Mcl-1, Cdk6 and 
GAPDH (Santa Cruz, Santa Cruz, CA). 
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